All In Biotech

Drug Trial Radar · NCT07716618

A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD)

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of SAL0120 Tablets in Patients With Chronic Kidney Disease (CKD).

Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 320 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

320

Planned (sponsor's estimate)

Start

Jan 17, 2025

Primary completion

May 27, 2026

Study completion Aug 31, 2026

Sponsor

Sponsor type
Industry
Collaborators
Salubris (Suzhou) Pharmaceutical Co., Ltd.
First posted
Jul 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, double-blind, placebo-controlled, parallel-design clinical trial designed to investigate the efficacy and safety of different doses of sal0120 tablets in patients with CKD.

Conditions

  • Chronic Kidney Disease

Interventions

  • SAL0120 1mgDrug

    SAL0120 1mg

  • SAL0120 2mgDrug

    SAL0120 2mg

  • SAL0120 4mgDrug

    SAL0120 4mg

  • PlaceboDrug

    placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The baseline relative change in UACR;The change from baseline in UACR across SAL0120 dose groupsTime frame: at 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.